ROTARY SENSOR MODULE WITH AXIAL SWITCH (Fri, 29 Aug 2014)
Sensor assembly comprising a first rotary sensor part with a plurality of individual electrically conducting sensor areas arranged in a pattern, a second rotary sensor part arranged rotationally relative to the first portion, the second part comprising a plurality of contact structures adapted to be in contact with conducting sensor areas on the first sensor rotary part. The contact structures are configured to engage and connect different sensor areas as the first and second part of the rotary sensor rotate relative to each, the created connections being indicative of a rotational position between the first and second portions. One of the contact structures is an actuatable contact structure being axially moveable relative to the first portion and having a connected position in which the actuatable contact structure is in contact with a sensor area and a dis-connected position in which the actuatable contact structure is not in contact with a sensor area.
>> read more

DOSE CAPTURING CARTRIDGE MODULE FOR DRUG DELIVERY DEVICE (Fri, 29 Aug 2014)
An electronic logging unit adapted to be housed in a drug-filled cartridge having an axially displaceable piston and an outer cavity formed between the piston and the cartridge proximal opening, the logging unit comprising a general axis, a first distal portion adapted to engage the cartridge piston, and a second proximal portion adapted to engage a rotating element having a rotational axis corresponding to the general axis. The unit is provided with sensor means adapted to detect the amount of relative rotation between the first and second portions, and storage means adapted to store data representing detected amounts of relative rotation.
>> read more

DRUG DELIVERY DEVICE WITH DOSE CAPTURING MODULE (Fri, 29 Aug 2014)
A drug delivery system is provided comprising drug expelling means adapted to expel a set dose from a drug-filled cartridge, the expelling means comprising a rotational member adapted to rotate relative to a housing and corresponding to a set and/or expelled dose, the system comprising a sensor adapted to detect a set and/or an expelled dose. The sensor comprises a first portion mounted to and rotating with the rotational member, and a second portion comprising a second rotary sensor part mounted non-rotationally relative to the housing. The first portion comprises electronic circuitry, and a first rotary sensor part, and the second portion comprises a second rotary sensor part mounted non-rotationally relative to the housing. The first and second rotary sensor parts rotate relative to each other during set- ting and/or expelling of a dose of drug.
>> read more

INJECTION NEEDLE HAVING SHIELD ACTIVATED VALVE (Fri, 22 Aug 2014)
The present invention relates to a needle assembly having a build-in valve (30). The needle assembly is build up from a hub (20) carrying a needle cannula (10) and a telescopically movable shield (40) which axially covers the distal tip (13) of the needle cannula (10) be- tween injections. The valve (30) is operated by the shield (40) and is arranged such that it is closed when the distal tip (13) of the needle cannula (10) is covered by the shield (40) and is opened when the telescopically movable shield (40) has been retracted a specific distance (X) proximally to the distal tip (13) of the distal cannula part (11).
>> read more

A NON-AXIAL WORKING END-OF CONTENT MECHANISM AND AN INJECTION DEVICE COMPRISING THE SAME (Fri, 08 Aug 2014)
The invention relates to a non-axial working End-of-Content mechanism which is geared by a hypocycloid gearing. The EoC mechanism comprises a first element (30, 109) having a first internal surface (36, 136) with a first internal diameter (D), and an EoC element (50, 150) having a second external surface (56, 156) with a second external diameter (d) being smaller that the first internal diameter (D). The EoC element (50, 150) is located inside the first internal diameter (D) of the first element (30, 109) and the first element (30, 109) and the EoC element rotates relatively to each other in a gearing ratio. The EoC element (150, 150) thus operating as the inner rolling circle of a hypocycloid counting the numbers of relative rotations. The EoC mechanism further has stopping means (45, 55; 1 13, 155)) provided for stopping the relative rotation in a predetermined position which position correlates to the initial injectable content of drug in the injection device such that a user cannot at any time set a dose larger than the quantum left in the injection device at any time.
>> read more

MEDICAL INJECTION SYSTEM WITH DOSE CAPTURING (Fri, 18 Jul 2014)
The present invention relates to a medical injection system comprising an injection device (100) and a dose capturing unit (20). The injection device (100) incorporates expelling means (101) for setting and expelling a set dose amount of a drug from a reservoir. The expelling means (101) further comprises mechanical energy storage unit adapted to drive the expelling movement and a movable dosing member (350). In one form the dose capturing unit (20) is configured for being releasably attached to the injection device (100). The dose capturing unit (20) comprises a dose sensor (20d) configured to capture data relating to the movement of the dosing member (350) during dose expelling. When the dose capturing unit (20) is at tached to the injection device (100), the systems forms a speed limiting means (F, M) to limit the speed of the dosing member (350) during dose expelling so that a force that counteracts the force exerted by the mechanical energy storage unit is generated.
>> read more

HIGH TEMPERATURE DEAD END ANTIBODY FILTRATION (Fri, 04 Jul 2014)
The invention relates to a method of dead end filtration of a highly concentrated antibody containing solutions at a temperature above room temperature, wherein the filter flow rate is increased compared to filtration at a room temperature, the filter flow rate is kept constant and the yield increased compared to filtration at a room temperature.
>> read more

NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY (Fri, 27 Jun 2014)
The present invention provides novel glucagon-like protein-1(GLP-1) receptor agonist compounds that promote cholesterol efflux. The present invention also provides compositions comprising the novel glucagon-like protein-1(GLP-1) receptor agonist compounds, and relates to the use of said compounds in therapy, to methods of treatment comprising administration of said compounds to patients, and to the use of said compounds in the manufacture of medicaments.
>> read more

A NEEDLE DEVICE (Fri, 27 Jun 2014)
The invention relates to a needle device which is made from a housing (1, 2, 3) having a distal wall (4) with a front (5). The housing further holds a compartment (21, 22) containing a liquid drug to be expelled. A needle cannula (10) for expelling the liquid drug having a distal end (1 1 ) and a proximal end (12) is also present, the needle cannula (10) being axially movable from a first position to a second position; The first position being a position in which the distal end (1 1 ) of the needle cannula (10) is retracted proximally behind the front (5) of the distal wall (4) of the housing (1, 2, 3), and wherein the proximal end (12) of the needle cannula (10) is located outside the first compartment (21, 22), and the second position being a position in which the distal end (1 1 ) of the needle cannula (10) is extended distally to the front (5) of the distal wall (4) of the housing (1, 2, 3), and wherein the proximal (12) end is located inside the compartment (21, 22).
>> read more

Antibodies (Thu, 26 Jun 2014)
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
>> read more

Anti-IL21 antibodies for use in the treatment of cardiovascular diseases (Thu, 26 Jun 2014)
The present invention relates to treatment of cardiovascular diseases and arthero-sclerosis. In particular, the present invention relates to use of therapeutic antibodies.
>> read more

Anti-IL21 antibodies for use in the treatment of nephropathies (Thu, 26 Jun 2014)
The present invention relates to treatment of nephropathy. In particular, the present invention relates to treatment of nephropathy using therapeutic antibodies.
>> read more

IL-21 EPITOPE AND IL-21 LIGANDS (Fri, 20 Jun 2014)
<p id="p-0001" num="0000">The present invention relates to IL-21 ligands, such as e.g. antibodies, as well as use thereof.</p>
>> read more

Factor IX: Remodeling and Glycoconjugation of Factor IX (Fri, 20 Jun 2014)
<p id="p-0001" num="0000">The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.</p>
>> read more

Glycopegylated Factor IX (Fri, 06 Jun 2014)
<p id="p-0001" num="0000">Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.</p>
>> read more

INJECTION DEVICE WITH INTEGRATED NEEDLE SHIELD (Fri, 06 Jun 2014)
The invention relates to injection device, which device comprises an outer housing (1), a syringe body (10) and a needle shield (30). Both the syringe body (10) and the needle shield (30) are telescopically movable mounted to the housing (1) such that the needle shield (30) is movable relatively to the housing (1) between a first position and a second position, and the syringe body (10) is movable in relation to the housing (1) between an extended position and a retracted position.
>> read more

Anit-Human Interleukin-20 Antibodies (Fri, 23 May 2014)
<p id="p-0001" num="0000">Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.</p>
>> read more

MEDICAL DELIVERY SYSTEM COMPRISING LOCKING RING WITH L-SHAPED GROOVES (Fri, 23 May 2014)
<p id="p-0001" num="0000">A medical delivery system comprising a container which is adapted to be fastened to a dosing assembly. One of the container and the dosing assembly comprises a rotatable element adapted to cooperate with the other one of the container and the dosing assembly, so as to lock/fasten the container to the dosing assembly. Furthermore, the present invention relates to a container and a dosing assembly for use in the medical delivery system.</p>
>> read more

Method of acylating a peptide or protein (Fri, 23 May 2014)
<p id="p-0001" num="0000">A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.</p>
>> read more

DRUG DELIVERY DEVICE WITH VARIABLE DOSE SETTING MECHANISM (Fri, 23 May 2014)
A drug delivery system (1) comprising first (35) and second reservoir units (30) with first and second identifiers (32), and a main unit (10) adapted to receive either of the first (35) and second reservoir units (30) in a mounted position. The main unit (10) comprises drug expelling means having dose setting means (11, 1, 14, 15, 19) comprising a rotational dose setting member allowing a user to set a desired dose size for the given drug, the dose size being set in fixed increments for a given state. The drug expelling means has a first state in which an increment corresponds to a first volume of drug, and a second state in which an increment corresponds to a second volume of drug, wherein the drug expelling means is set in the first state by means of the first identifier when a first reservoir unit is mounted, and the drug expelling means is set in the second state by means of the second identifier when a second reservoir unit is mounted.
>> read more

DRUG DELIVERY DEVICE WITH INTEGRATED SHIELD (Fri, 16 May 2014)
Drug delivery system comprising a main portion (10) with a drug reservoir (30) having a distal outlet, and a shield (20) moveably mounted to the main portion, the shield being displaceable by a user between a shielding and a non-shielding position. The shield has an opening (22) and closure means (25) for closing the opening, the closure means being reversible actuatable between a closed state and an open state. When the shield is in the shielding position, with the closure means in the closed state, the shield covers the distal outlet of a mounted reservoir, and when the shield is in the non- shielding position, with the closure means in the open state, then the distal outlet of a mounted drug reservoir can protrude through the opening.
>> read more

Stabilised Compositions of Factor VII Polypeptides (Fri, 09 May 2014)
<p id="p-0001" num="0000">The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.</p>
>> read more

DRUG DELIVERY DEVICE WITH SHIELD OPERATED NEEDLE ACTUATOR (Fri, 09 May 2014)
A drug delivery device comprises a shield (30) moveably mounted to a main portion and being displaceable by a user between a shielding and a non-shielding position, wherein a needle assembly (50) can be mounted on a reservoir, the shield covering the needle assembly in the shielding position. The needle assembly is moveable between a dis-connected and connected position in fluid communication with the reservoir. In such an arrangement a mounted needle assembly is moved from the dis-connected to the connected position when the shield is moved from the shielding to the non-shielding position, and moved from the connected to the dis-connected position when the shield is moved from the non-shielding to the shielding position.
>> read more

A PRE-FILLED DISPOSABLE INJECTION DEVICE (Fri, 02 May 2014)
The present invention relates to a pre-filled disposable injection device and a needle cannula in combination. The prefilled disposable injection device (1) is made from a housing (2) con- taining a non-exchangeable cartridge (10) for storing a liquid drug sufficient for a number of injections. The proximal end of the pre-filled injection device (1) carries the dose setting but- ton (3) and the distal end carries the needle cannula (20) having a lumen (21) through which the settable dose is expelled. The distal end (23) of the needle cannula (20) is covered by a telescopic needle covering shield (30) which shield (30) can operate between a first position covering the tip (24) of the needle cannula (20) and a second retracted position allowing an injection to be performed. The shield (30) carries a cleaner (50) which cleans at least the tip (24) of the needle cannula (20) between successive injections such that the prefilled injection device can be used without changing the needle cannula (20) during its life cycle.
>> read more

Glycopegylated factor IX (Fri, 25 Apr 2014)
<p id="p-0001" num="0000">Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.</p>
>> read more

FATTY ACID ACYLATED D-AMINO ACIDS FOR ORAL PEPTIDE DELIVERY (Fri, 25 Apr 2014)
The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's.
>> read more

FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY (Fri, 25 Apr 2014)
The present invention relates to oral pharmaceutical compositions comprising a GLP-1 peptide and a fatty acid acylated amino acid and use thereof.
>> read more

FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY (Fri, 25 Apr 2014)
The present invention relates to growth hormone compositions comprising a fatty acid acylated amino acids (FA-aa's), which may be used in pharmaceutical compositions such as pharmaceutical compositions for oral administration of growth hormone.
>> read more

SPRING DRIVEN INJECTION DEVICE (Fri, 25 Apr 2014)
The present invention relates to a torsion spring driven injection device for delivering multiple set doses of a liquid drug from a cartridge by moving a plunger forward inside the cartridge. The torsion spring (134) applies a rotational torque onto a drive member (120) engaging a piston rod (115) which is then driven forward by this rotation. The piston rod driver can be coupled and de-coupled from the torsion spring mechanism. In the de-coupled position, the piston rod driver is freely rotatable and can thus rotate if the piston rod is moved axially. A further torsion arrangement (124) is preferably provided such that a torque is build up between the piston rod driver and the housing whenever the piston rod is moved backwards. This torsion arrangement urges the piston rod driver to rotate in a direction bringing the piston rod forward into abut- ment with the plunger.
>> read more

FACTOR VII CONJUGATES (Fri, 25 Apr 2014)
The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
>> read more

COAGULATION FACTOR VII POLYPEPTIDES (Fri, 25 Apr 2014)
The present invention relates to modified coagulation Factor VII (Factor VII) polypeptides having coagulant activity as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
>> read more

Growth hormones with prolonged in-vivo efficacy (Fri, 18 Apr 2014)
<p id="p-0001" num="0000">The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.</p>
>> read more

LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE (Fri, 18 Apr 2014)
The invention concerns a liquid pharmaceutical composition comprising: A Factor VIIa polypeptide; A buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and An active site stabilizing agent, which is a compound exhibiting a Fit value >0 in the pharmacophore model described by the Pharmacophore Model and Methods Description when using the parameter settings described by the Pharmacophore Model and Methods Description, or a pharmaceutically acceptable salt of said compound.
>> read more

LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE (Fri, 18 Apr 2014)
The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VIIa polypeptide, a buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and an active site stabilizing agent, which is selected from the group of: (S)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; (R)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; and a mixture of the (S)- and (R)-forms or pharmaceutically acceptable salts thereof. The invention further relates to said composition for treatment of a Factor VII-responsive bleeding disorder; methods for preparing the liquid composition and for stabilizing Factor VIIa in a liquid aqueous composition; an air-tight container containing the liquid, aqueous pharmaceutical composition and optionally an inert gas; and a method of treating a Factor VII-responsive bleeding disorder in a patent.
>> read more

Polypeptides (Fri, 28 Mar 2014)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Fri, 28 Mar 2014)
<p id="p-0001" num="0000">The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K<sup>27</sup>, and the second K residue is designated K<sup>T</sup>; which derivative comprises two albumin binding moieties attached to K<sup>27 </sup>and K<sup>T</sup>, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH<sub>2</sub>)<sub>x</sub>—CO— and HOOC—C<sub>6</sub>H<sub>4</sub>-0-(CH<sub>2</sub>)<sub>y</sub>—CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH<sub>2</sub>)<sub>2</sub>—(O—(CH<sub>2</sub>)<sub>2</sub>)<sub>k</sub>—O—(CH<sub>2</sub>)<sub>n</sub>—CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.</p>
>> read more

Insulin analogues with an acyl and alkylene glycol moiety (Thu, 20 Mar 2014)
An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.
>> read more

PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES (Fri, 14 Mar 2014)
<p id="p-0001" num="0000">Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.</p>
>> read more

Purification of Insulin (Fri, 14 Mar 2014)
<p id="p-0001" num="0000">The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self-association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/L<sub>cv</sub>); and b) eluting the insulin peptide from said solid phase material by means of an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75% by weight of the insulin peptide applied to the column in step (a).</p>
>> read more

GENERATION OF PANCREATIC ENDODERM FROM PLURIPOTENT STEM CELLS USING SMALL MOLECULES (Fri, 07 Mar 2014)
A method of producing pancreatic cells or pancreatic cell precursors expressing at least 5% PDX1/NKX6.1 double positive, comprising exposing definitive endoderm cells to an effective amount of one or more small molecules, to differentiate the human definitive endoderm cells into the pancreatic cells or pancreatic cell precursors. The present invention also relates to pancreatic endoderm cells produced by said methods and uses of said pancreatic endoderm cells.
>> read more

Injection device for performing medical injections (Thu, 06 Mar 2014)
The present invention concerns a prefilled injection device having a container and a dose setting mechanism encapsulated inside the housing. The injection device incorporates an axial variable connection such that the distance between the distal end of the piston rod means and the plunger is minimized preferably to zero during assembly. The container and the dose setting mechanism are then mutually fastened, e.g. by laser welding. Consequently, possible clearance in assembly process of the injection device is obviated and priming of the device before an injection becomes redundant.
>> read more

FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY (Fri, 28 Feb 2014)
<p id="p-0001" num="0000">The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.</p>
>> read more

A SPRING-LOADED INJECTION DEVICE WITH AN INJECTION BUTTON (Fri, 28 Feb 2014)
The present invention relates to a spring-loaded medical injection device for automatically ejecting set doses of a drug having an injection button (10). The injection device comprises a housing having a dose setting member (20) for straining an injection spring when setting the size of the dose to be injected and a release element (30) for releasing the strained injection spring to eject the set dose. The injection button (10) is movable in a distal direction against the bias of a return spring (1) and movable in a proximal direction by the force of the return spring (1). Further, the injection button (10) moves with it the release element from a first position to a second position. The release element (30) is further coupled to the injection button (10) by a plurality of fingers (31, 15) which disengages the injection button (10) from the release element (30) in the first position and engages the injection button (10) with the release element (30) in the second position, such that the injection button (10) can move a distance axially independently of the release element (30) in the first position and the injection button (10) and the release element (30) move axially together in the second position.
>> read more

MEDICAL INJECTION DEVICE WITH LARGE, MECHANICAL CIPHER DOSE DISPLAY (Fri, 21 Feb 2014)
<p id="p-0001" num="0000">An injection device is disclosed which comprises a housing (10) with a display for showing the size of a set dose. The display is formed from a number of individual ciphers (<b>11, 40</b>) which each comprises a plurality of segments (<b>13, 14</b>) extending horizontally and vertically. At the end of the injection device a dose setting element (<b>20</b>) is provided for allowing the user to set the size of the dose to be injected. Further, the display mechanism comprises a first pattern (<b>35</b>) for showing the vertical segments (<b>14</b>), and a second pattern (<b>25</b>) for showing the horizontal segments (<b>13</b>). The patterns (<b>25, 35</b>) are associated with the dose setting button (<b>20</b>) and arranged to be moved when the dose setting button (<b>20</b>) is operated. The injection device disclosed can have any number of ciphers (<b>11, 40</b>) which is coupled to each other in order to show to the user the size of any dose set.</p>
>> read more

LIQUID FACTOR VIII FORMULATIONS (Fri, 21 Feb 2014)
The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a p H from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII.
>> read more

FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY (Thu, 20 Feb 2014)
The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.
>> read more

COUPLING OF POLYPEPTIDES AT THE C-TERMINUS (Fri, 14 Feb 2014)
<p id="p-0001" num="0000">The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.</p>
>> read more

NOVEL GLUCAGON ANALOGUES (Thu, 06 Feb 2014)
The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
>> read more

Human Insulin Analogues and Derivatives Comprising Cysteine Substitutions (Fri, 31 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to human insulin analogues containing a substituting cysteine, to human insulin derivatives containing a PEGylated substituting cysteine and methods of making such. The compounds of the invention may be useful for the treatment of diabetes.</p>
>> read more

Novel Glucagon Analogues (Fri, 31 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.</p>
>> read more

Medical Injection Device (Fri, 24 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to injection devices for injecting a dose of a medicament. The injection device (<b>100</b>) incorporates a housing (<b>101</b>), a needle assembly (<b>150</b>) and a cover (<b>200</b>). The needle assembly (<b>150</b>) comprises an injection needle (<b>152, 153</b>) accommodated in a needle container (<b>151</b>) having an opening which in a storage state of the injection device (<b>100</b>) is sealed by a film seal (<b>155</b>). The cover may include sections (<b>201, 202</b>) arranged movable relative to the housing (<b>101</b>). The injection device (<b>100</b>) is so configured that upon movement of the cover sections (<b>201, 202</b>) relative to the housing (<b>101</b>) the film seal (<b>155</b>) is changed from a sealing state to an unsealing state for shifting the injection device (<b>100</b>) into a ready-to-administer state.</p>
>> read more

LEPTIN DERIVATIVES (Fri, 17 Jan 2014)
<p id="p-0001" num="0000">The invention relates to Leptin derivatives, compositions and therapeutic use there-of.</p>
>> read more

AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF (Fri, 17 Jan 2014)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA (Fri, 17 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.</p>
>> read more

NOVEL USE OF INSULIN DERIVATIVES (Fri, 17 Jan 2014)
This invention relates to insulin derivatives having long duration of action. The insulin derivatives have been found to be useful for the treatment of diabetes, and in particular for less frequent administration to the diabetic patients, in particular as seldom as about once weekly.
>> read more

Peptides Derivatized with A-B-C-D- and their Therapeutical Use (Fri, 10 Jan 2014)
<p id="p-0001" num="0000">The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.</p>
>> read more

LONG-ACTING IL-1 RECEPTOR ANTAGONISTS (Fri, 10 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to IL-1 receptor antagonist compounds, compositions and use thereof as well as methods for preparation thereof.</p>
>> read more

USE OF LONG-ACTING GLP-1 PEPTIDES (Fri, 10 Jan 2014)
The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.
>> read more

IL-20 EPITOPES AND IL-20 LIGANDS (Fri, 10 Jan 2014)
The present invention relates to IL-20 ligands, such as e.g. antibodies, binding to a novel binding site as well as use thereof.
>> read more

SPRING DRIVEN INJECTION DEVICE (Sat, 04 Jan 2014)
The present invention relates to an injection device for automatic torsion spring driven injection of a liquid drug. The injection device is of the type wherein a telescopically movable needle shield activates the release of the torque of the torsion spring to drive the injection when the needle shield is moved from its extended position to a retracted position. The injection device further has a needle holder carrying the injection needle, which needle holder is axially movable both in relation to the housing and in relation to the needle shield. It is therefore possible to retract the needle shield in relation to the housing and at the same time move the needle holder to its extended position such that the injection needle is presented outside the needle shield thereby providing for easy exchange of the injection needle.
>> read more

SHIELD LOCK FOR SPRING DRIVEN INJECTION DEVICE (Sat, 04 Jan 2014)
The present invention relates to an injection device for automatic torsion spring driven injec- tion of a liquid drug. The injection device is of the type wherein a telescopically movable needle shield (20) activates the release of the torque of the torsion spring to drive the injection when the needle shield is moved from its extended position to a retracted position. The injection device is provided with a needle interface (30) carrying the injection needle, which needle interface is provided with means (32) preventing axial movement of the shield when no injection needle is mounted. Further, other means are provided to restrain the needle shield in the retracted position when the injection device is its "zero" position such that a user has access to the injection needle in order to exchange the injection needle.
>> read more

GLP-1 PARTICLES AND COMPOSITIONS (Fri, 03 Jan 2014)
<p id="p-0001" num="0000">The present invention relates to compositions and particles comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised that the particle comprises a core and a surrounding layer, the core comprising the GLP-1 compound and the divalent metal, and the surrounding layer comprising the polycationic compound. The invention is particularly useful for the treatment of metabolic diseases, including diabetes.</p>
>> read more

Glucagon-like peptide-1 derivatives and their pharmaceutical use (Thu, 02 Jan 2014)
The invention relates to protracted Glucagon-Like Peptide- 1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
>> read more

TABLET FORMULATION COMPRISING A PEPTIDE AND A DELIVERY AGENT (Sat, 28 Dec 2013)
The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.
>> read more

Glycopegylated Factor IX (Fri, 27 Dec 2013)
<p id="p-0001" num="0000">Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.</p>
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER (Fri, 20 Dec 2013)
<p id="p-0001" num="0000">The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from</p> <p id="p-0002" num="0000"> <br/> <?in-line-formulae description="In-line Formulae" end="lead"?>HOOC—(CH<sub>2</sub>)<sub>x</sub>—CO-*, and  Chem. 1:<?in-line-formulae description="In-line Formulae" end="tail"?> </p> <p id="p-0003" num="0000"> <br/> <?in-line-formulae description="In-line Formulae" end="lead"?>HOOC—C<sub>6</sub>H<sub>4</sub>-0-(CH<sub>2</sub>)<sub>y</sub>—CO-*,  Chem. 2:<?in-line-formulae description="In-line Formulae" end="tail"?> </p> <p id="p-0004" num="0000">in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises</p> <p id="p-0005" num="0000"> <br/> <?in-line-formulae description="In-line Formulae" end="lead"?>*-NH—(CH<sub>2</sub>)<sub>q</sub>—CH[(CH<sub>2</sub>)<sub>w</sub>—NH<sub>2</sub>]—CO-*,  Chem. 3:<?in-line-formulae description="In-line Formulae" end="tail"?> </p> <p id="p-0006" num="0000">wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.</p>
>> read more

Antagonistic DR3 ligands (Fri, 20 Dec 2013)
<p id="p-0001" num="0000">The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.</p>
>> read more

PREPARATION COMPRISING INSULIN, NICOTINAMIDE AND ARGININE (Fri, 20 Dec 2013)
Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and arginine.
>> read more

ANTAGONISTIC DR3 LIGANDS (Fri, 13 Dec 2013)
<p id="p-0001" num="0000">The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR<sup>3 </sup>ligands useful for treating inflammatory diseases.</p>
>> read more

FAST-ACTING INSULIN IN COMBINATION WITH LONG-ACTING INSULIN (Fri, 13 Dec 2013)
<p id="p-0001" num="0000">Insulin preparations comprising a long-acting insulin compound, a fast-acting insulin compound, a nicotinic compound and an amino acid.</p>
>> read more

PURIFICATION OF INSULIN (Thu, 12 Dec 2013)
The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self- association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/L<sb>cv</sb> ); and b)eluting the insulin peptide from said solid phase material by means of an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75 % by weight of the insulin peptide applied to the column in step (a).
>> read more

IL-21 LIGANDS (Fri, 06 Dec 2013)
<p id="p-0001" num="0000">The present invention relates to IL-21 ligands binding to a discontinuous epitope on the surface of the IL-21 molecule as well as use thereof.</p>
>> read more

DIAL-DOWN MECHANISM FOR WIND-UP PEN (Fri, 06 Dec 2013)
The invention relates to a torsion spring driven injection device having a dial-down mechanism for dialling down a selected dose size. The torsion spring (2) is strained when setting a dose by rotating a proximally located dose setting button(30) relatively to the housing in a first direction and unstrained when rotating the same dose setting button (30) in a second direction opposite the first direction. In order to secure the torsion spring (2) in its strained position a one-way ratchet mechanism is provided. This one-way ratchet mechanism comprises a fixation element (1) coupled to the housing and having a toothing (6) and a ratchet element (20) having at least one ratchet arm (22) engaging the fixation element (1) and which ratchet element (20) is operational coupled to the dose setting button (30). The dose setting button (30) directly engages the at least one ratchet arm (22) when the dose setting button (30) is rotated in the second direction which releases the at least one ratchet arm (22) from the toothing (6) of the fixation element (1) and allows the ratchet element (20) to rotate relatively to the fixation element (1) in the second direction under influence of the torsion spring (2).
>> read more

PANCREATIC POLYPEPTIDE COMPOUNDS AND USE (Fri, 06 Dec 2013)
The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.
>> read more

STABILISED PROTEIN SOLUTIONS (Fri, 22 Nov 2013)
The invention relates to a method of stabilizing highly concentrated protein solutions during ultrafiltration by addition of sucrose to the highly concentrated protein solution, in particular, but not exclusively to a method of stabilizing highly concentrated antibody solutions during ultrafiltration by addition of sucrose to the highly concentrated antibody solution.
>> read more

Needle Cannula with a Collapse Zone (Fri, 15 Nov 2013)
<p id="p-0001" num="0000">A metallic cylindrical tubular needle cannula (<b>1</b>) is subjected to a metal etching liquid inside the lumen (<b>7</b>) thereby increasing the inside diameter and enhancing the flow properties while maintaining the outside appearance. The inside wall (<b>5</b>) is further provided with a collapse zone (<b>10</b>) manufactured by radiating heat (<b>11</b>) to a specific outside area of the needle cannula (<b>1</b>) thereby increasing the aggression of the etchant. Further two different methods of in- process testing of the inside diameter of the needle cannulae using any fluid gas are disclosed.</p>
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Fri, 15 Nov 2013)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC-(CH2)x-CO-*, and Chem. 2: HOOC-C6H4-O-(CH2)y-CO-*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *-NH-(CH2)q-CH[(CH2)w-NR1R2]-CO-*, which is connected at its CO-* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *-H or *-CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Fri, 15 Nov 2013)
The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first K residue and a second K residue, at positions corresponding to position 26, and 34, respectively, of GLP-1(7-37) (SEQ ID NO:1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is Chem. 2: HOOC-C6H4-0-(CH2)y-CO-*, in which y is an integer in the range of 6-13; and the linker comprises Chem. 3a: *-NH-(CH2)q-CH[(CH2)w-NR1R2]-CO-*, wherein q is an integer in the range of 0-5, R1 and R2 independently represent *-H or *-CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.
>> read more

THERAPEUTIC ANTIBODIES (Fri, 08 Nov 2013)
<p id="p-0001" num="0000">The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.</p>
>> read more

METHODS RELATED TO TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS (Fri, 08 Nov 2013)
The present invention provides a method for treating an inflammatory disease or disorder in a patient suffering from said disease, which method comprises administering a therapeutic amount of an anti-inflammatory agent to said patient, wherein said patient is seropositive.
>> read more

PHARMACEUTICAL COMPOSITION (Fri, 08 Nov 2013)
A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a diseasein a subject in need thereof where administration of insulin would be of benefit to said subject is described. The combination is administered in an amount to achieve a beneficial glycaemic control in said subject as determined by the levels of HbA1c in said subject after administration of said combination at the largest meal of the day for said subject; wherein said beneficial glycaemic control by said combination is superior to any glycaemic control achieved by an equivalent dose of IGlar in said subject as determined by the levels of HbA1c in said subject after administration of IGlar for said subject and/or wherein said beneficial glycaemic control by said combination comprises decreasing the levels of HbA1c in said subject to about 7 or less after administration of said combination at the largest meal of the day; wherein said first insulin- like compound is longer acting than the second insulin-like compound; wherein said combination is administered at the largest meal of the day for said subject; wherein said first insulin-like compound is at least a long acting insulin, preferably an ultra long acting insulin; wherein said first insulin-like compound is a derivative of a naturally occurring insulin or is an insulin analogue; and wherein said first insulin-like compound has a side chain attached to the a-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula (I):- W-X-Y-Z.
>> read more

PHARMACEUTICAL COMPOSITION SUITABLE FOR TREATMENT OF HAEMOPHILIA (Fri, 01 Nov 2013)
The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
>> read more

HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS (Fri, 01 Nov 2013)
Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.
>> read more

DRUG DELIVERY DEVICE AND METHOD FOR DETECTION OF AN END-OF-DOSE CONDITION (Fri, 01 Nov 2013)
Method for detecting an end-of-dose condition in a pressurized system, comprising the steps of (a) providing a system having a fluid-filled variable volume reservoir comprising an elastically deformable portion and an outlet, pressurizing means, and means for detecting a property of the elastically deformable portion which varies with the internal pressure in the reservoir, (b) pressurizing the reservoir to expel a desired amount of fluid by applying a force, thereby deforming the elastically deformable portion, (c) measuring, after the actuating step, a property related to the elastically deformable portion as it regains its initial configuration, (d) comparing a value for the measured property with one or more threshold values, and (e) providing a user with an indication when a given threshold value has been reached, and/or when a given threshold value has not been reached within a given period of time.
>> read more

Preparation Comprising Insulin, Nicotinamide and an Amino Acid (Fri, 25 Oct 2013)
<p id="p-0001" num="0000">Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.</p>
>> read more

POLYPEPTIDES (Fri, 25 Oct 2013)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

MEDICAL INJECTION DEVICE COMPRISING A SECONDARY SAFETY LIMITER (Fri, 25 Oct 2013)
The present invention relates to an injection device (1) for setting and injecting set doses from a held drug cartridge (10). The injection device (1) comprises a housing (110,120,130, 140), a piston rod (800), a rotatable driver (500, 700) and a dose setting device (400). The dose setting device (400) comprises a predetermined stop to limit the amount of an expelled dose corresponding to the amount of a set dose. A secondary stop limiter includes first (700) and second (270) components and a secondary stop track follower (950) arranged between the first (700) and second (270) components. If the predetermined stop fails to stop the driver (500, 700) at the end of injection, the secondary stop track follower (950) moves towards a safety stop (708) to prevent the driver (500, 700) from rotating further.
>> read more

MEDICAL INJECTION DEVICE (Fri, 25 Oct 2013)
The present invention relates to an injection device (1 ) for setting and injecting set doses from a held drug cartridge (10). The injection device (1 ) comprises a housing (1 10,120,130, 140), a piston rod (800), a rotatable driver (500, 700) and a dose control member (350). A stored energy source (560) is configured to drive rotation of the driver (500, 700) to cause the piston rod (800) to expel a set dose. The dose control member (350) rotates during dose setting and during dose expelling. A first clutch (C1) is arranged between the dose control member (350) and the driver (500, 700). A second clutch (C2) is arranged between the driver (500, 700) and the housing (110, 120, 130, 140) to control the expelling movement. During dose setting the first clutch (C1) is disengaged and the second clutch (C2) is engaged. During dose expelling the first clutch (C1) is engaged and the second clutch (C2) is disengaged.
>> read more

MEDICAL DELIVERY DEVICE WITH REGIMEN IDENTIFICATION FEATURE (Fri, 25 Oct 2013)
A drug delivery system comprising a controller adapted to detect when a given user-actuated operation being part of the expelling of an amount of drug is performed, record detected operations as a function of time, and estimate, based on recorded operations, time parameters for the detected operations, thereby providing time parameters for a medical regimen on which the detected operations are assumed to be based upon.
>> read more

HUMAN AMYLIN ANALOGUES (Fri, 25 Oct 2013)
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
>> read more

MEDICAL INJECTION DEVICE WITH TIME DELAY INDICATOR (Fri, 18 Oct 2013)
The present invention relates to an indicating device (100) for use with medical injection devices for administering a drug into the body of a subject user wherein the indicating device is configured for indicating after administration that a dose of the drug actually has been administered and for maintaining this indication until lapse of a pre-defined time interval. The time delay indicator (120) disclosed may be based on a mechanical time delay device and includes a visual indicator that is controlled by the mechanical time delay device for signalling the status of the device during lapse of the pre-defined time interval. The injection device (100) includes a force absorbing structure (110, 111, 130, 140, 150) adapted to absorb activation forces exerted on an activation member (110, 111) and exceeding a pre-defined magnitude from being transferred to the time delay indicator (120).
>> read more

INSULIN FORMULATIONS (Fri, 18 Oct 2013)
A stable pharmaceutical formulation containing an insulin derivative can conveniently be prepared by adding glycerol, phenol, m-cresol and zinc ions to it.
>> read more

THERAPEUTIC FACTOR VIII ANTIBODIES (Fri, 11 Oct 2013)
<p id="p-0001" num="0000">The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.</p>
>> read more

Piston Rod Foot (Fri, 11 Oct 2013)
<p id="p-0001" num="0000">The invention relates to a medical drug delivery apparatus which comprises a cartridge (<b>1</b>) being closed at one end by a flexible membrane (<b>2</b>) and at the opposite end by a movable piston (<b>10</b>). The movable piston rod (<b>19</b>) is moved forward by a piston rod (<b>20</b>). In order to distribute the force from the piston rod (<b>20</b>) to the movable piston (<b>10</b>) a piston rod foot (<b>30</b>) is provided sandwiched between the piston rod (<b>29</b>) and the movable piston (<b>10</b>) The piston rod foot (<b>30</b>) provided between the piston rod (<b>20</b>) and the movable piston (<b>10</b>) has a plurality of arms (<b>34</b>) extending in a direction perpendicular to a longitudinal axis (X) of the cartridge (<b>1</b>) and which arms (<b>34</b>) engages the inner wall (<b>4</b>) of the cartridge (<b>1</b>) thereby obtaining geometric guidance or generating a force of friction between the piston rod foot (<b>30</b>) and the inner wall (<b>4</b>) of the cartridge (<b>1</b>).</p>
>> read more

Method for the Production of Proteins (Fri, 04 Oct 2013)
<p id="p-0001" num="0000">The present invention relates to a process for the purification of a protease.</p>
>> read more

DRUG DELIVERY DEVICE WITH PISTON PROXIMITY SENSING (Fri, 04 Oct 2013)
Drug delivery device with electronically controlled and axially displaceable piston drive member (10) adapted to engage a loaded cartridge piston. The piston drive member is moveable between a proximal loading position in which a cartridge can be received and a distal loaded position in engagement with the piston. A proximity sensor (11,12) provides a varying output indicative of a varying distance between the piston drive member and the piston. A controller (30) coupled to the proximity sensor is configured to control movement of the piston drive member from the loading position to the loaded position and stop movement when the controller based on input from the proximity sensor system determines that the loaded position has just been reached. By this arrangement it is prevented that a drug-filled cartridge is pressurized during the loading and initializing procedure.
>> read more

FVIIA-STF COMPLEXES EXHIBITING EXOSITE-MEDIATED SUPER ACTIVITY (Fri, 04 Oct 2013)
Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy.
>> read more

Antibodies Against Tissue Factor Pathway Inhibitor (Fri, 27 Sep 2013)
<p id="p-0001" num="0000">The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.</p>
>> read more

FGF21 ANALOGUES AND DERIVATIVES (Fri, 27 Sep 2013)
<p id="p-0001" num="0000">Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.</p>
>> read more

Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor (Fri, 27 Sep 2013)
<p id="p-0001" num="0000">The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.</p>
>> read more

REMINDER PROGRAMMING DEVICE AND METHOD (Fri, 27 Sep 2013)
<p id="p-0001" num="0000">An electronically controlled reminder device is adapted to be set in a programming mode by a user, perform a user-actuated operation, and detect when a user-actuated operation is performed. When in programming mode the device is adapted to record and set reminders in accordance with a detected time pattern of operation(s) of the device, wherein the programming mode is activated for a pre-determined number of operations or for a pre-determined period of time, after which the device automatically returns to the operational mode in which it provides reminders to the user based on the recorded time pattern of operations. Thus, normal use of the device provides automatic programming of the reminder scheme.</p>
>> read more

Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor (Fri, 27 Sep 2013)
<p id="p-0001" num="0000">The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.</p>
>> read more

COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF (Fri, 27 Sep 2013)
The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.
>> read more

COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF (Fri, 27 Sep 2013)
The invention relates to granules and pharmaceutical compositions comprising a salt of N- (8 - (2 -hydroxybenzoyl) amino) caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.
>> read more

REVOLVING NEEDLE MAGAZINE (Fri, 27 Sep 2013)
A needle magazine (1, 100) attachable to an injection device containing a liquid drug and which magazine (1, 100) comprises a main part (10, 110) and revolving part (20, 120) which can be rotated to bring a selected needle cannula (35, 135) into an injection position. The magazine (1, 100) is provided with a centrally located tube (13, 113) for penetrating into the injection device and has an internal conduit (14, 114, 115) for guiding the liquid drug from the tube (13, 113) and to a peripheral area of the magazine (1, 100). In this peripheral area a plurality of needle cannulae (35, 135) are provided which needle cannulae (35, 135) successively can be brought into liquid communication with the liquid drug in the conduit (14, 114, 115) by axial movement of the revolving part (20, 120).
>> read more

Combination therapy (Thu, 26 Sep 2013)
There is provided a monoclonal antibody and an IL-21 polypeptide for use in treating cancer, wherein said monoclonal antibody binds to killer lg-like receptors (KIR).
>> read more

TREATING DIABETES USING INHIBITORS OF IL-1 (Fri, 20 Sep 2013)
<p id="p-0001" num="0000">The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.</p>
>> read more

Novel GLP-1 Derivatives (Fri, 20 Sep 2013)
<p id="p-0001" num="0000">Novel polypeptide derivatives having protracted profile of action.</p>
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER (Thu, 19 Sep 2013)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1 : HOOC-(CH<sb>2</sb>)<sb>x</sb>-CO-*, and Chem. 2: HOOC-C<sb>6</sb>H<sb>4</sb>-0-(CH<sb>2</sb>)<sb>y</sb>-CO-*, in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises Chem. 3: *-NH-(CH<sb>2</sb>)<sb>q</sb>-CH[(CH<sb>2</sb>)<sb>w</sb>-NH<sb>2</sb>]-CO-*, wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Thu, 19 Sep 2013)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1 ), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem. : HOOC-(CH<sb>2</sb>)<sb>x</sb>-CO-* Chem. 2: HOOC-C<sb>6</sb>H<sb>4</sb>-0-(CH<sb>2</sb>)<sb>y</sb>-CO-* Chem. 3: R<sp>2</sp>-C<sb>6</sb>H<sb>4</sb>-(CH<sb>2</sb>)<sb>z</sb>-CO-*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, and R<sp>2</sp> is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *-NH-(CH<sb>2</sb>)<sb>2</sb>-(0-(CH<sb>2</sb>)<sb>2</sb>)<sb>k</sb>-0-(CH<sb>2</sb>)<sb>n</sb>-CO-*. wherein k is an integer in the range of 1 -5, and n is an integer in the range of 1 -5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
>> read more

GLP-1 PRODRUGS (Sat, 07 Sep 2013)
The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)- Xaa2-(OHis)-(GLP-1peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analogue thereof having a maximum of nineamino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1peptide) (Formula II), as well as specific intermediate products. The invention furthermore relates to a method of achieving release in vivo of an active and stabilised GLP-1 parent drug of the general formula II: (HOHis)-(GLP-1 peptide), by administering a GLP-1 prodrug; as well as to such GLP-1 prodrug, and such GLP-1 parent drug, respectively, for use as a medicament, in particular for use in the treatment and/or prevention of all forms of diabetes and related diseases. The prodrug may be used to alter the PK and/or absorption profile of the drug, for example to a desirable bell-shaped curve. The parent drug has a good biological activity, and is stabilised against degradation by DPP- IV.
>> read more

N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF (Sat, 07 Sep 2013)
The present invention is related to N-terminally fatty acid modified peptides or oligopeptides and pharmaceutical compositions comprising such.
>> read more

Combination therapy (Thu, 05 Sep 2013)
There is provided a monoclonal antibody and an IL-21 polypeptide for use in treating cancer, wherein said monoclonal antibody binds to killer lg-like receptors (KIR).
>> read more

AN END OF DOSE INDICATOR (Fri, 30 Aug 2013)
The present invention relates to a medical delivery apparatus which comprises a hollow container (2) filled with a liquid drug (3). The container (2) is closed at its distal end by a pierceable membrane (4) and provided with a plunger at its proximal open. Whenever a piston rod (20) moves the plunger (5) forward inside the container, a pressure is build up in the liquid drug (3) contained in the container (2). Further, a resilient element (33),such as a spring, is provided. This resilient element (33) can be activated to operate from a relaxed state to a tensed state upon activation of a dose injection mechanism during injection. The resilient element (33) is operated to its tensed state when during injection, the pressure is build up in the liquid drug (3) and secured in its tensed state as long as the pressure inside the container (2) is above a predetermined threshold value. When the pressure in the liquid drug (3) decreases below the predetermined threshold value, the tensed spring will operate into its relaxed state thereby providing an audible and/or tactile indication to the user that the pressure in the liquid drug (3) contained in the container (2) is below the predetermined threshold value.
>> read more

DRUG DELIVERY DEVICE WITH CARTRIDGE SNAP HOLDING FEATURE (Fri, 30 Aug 2013)
Drug delivery device comprising a cartridge holder adapted to receive and hold a cartridge in a loaded position,the cartridge holder comprising a distal opening adapted to receive the cartridge. The drug delivery device further comprises an expelling assembly adapted to engage and axially displace a piston in a loaded cartridge to thereby expel a dose of drug from the cartridge, and snap locking means acting on a cartridge being inserted in the cartridge holder, the snap locking means having a locked state in which the cartridge is held in the loaded position and an un-locked state in which the cartridge can be removed from the cartridge holder.
>> read more

DRUG DELIVERY DEVICE WITH FRONT LOADING FEATURE (Fri, 30 Aug 2013)
A drug delivery device adapted to receive a cartridge and hold it in a mounted position is provided, comprising a housing, an expelling assembly, and a front-loaded cartridge holder assembly adapted to receive and hold a cartridge in a mounted state. The assembly comprises cartridge holding means actuatable between a receiving state and a holding state, as well as a user operated actuation sleeve being rotationally actuatable relative to the housing between a loading state and an operational state, such that the cartridge holding means is actuated from the receiving state to the holding state when the actuation sleeve is actuated from the loading state to the operational state. The actuation sleeve is configured to enclose at least a portion of a mounted cartridge and is provided with inspection means allowing at least a portion of an enclosed cartridge portion to be visually inspected.
>> read more

MEDICAL CONTAINER PROTECTED AGAINST CRACKING (Fri, 23 Aug 2013)
<p id="p-0001" num="0000">Medical containers made of plastic can be protected against cracking by adding a layer of a poly-paraxylylene structure to said container.</p>
>> read more

Medical Injection Device (Fri, 23 Aug 2013)
<p id="p-0001" num="0000">The present invention relates to injection devices for injecting a medicament from a cartridge (<b>600</b>) through a needle cannula (<b>510</b>). The injection device (<b>100</b>) includes an actuator (<b>330, 360</b>) for driving a piston driver (<b>310</b>) and includes an end of stroke limiter (<b>341, 611</b>). When the piston driver (<b>310</b>) is arrested by the end of stroke limiter (<b>341, 611</b>) a shielding driver (<b>370</b>) is automatically triggered to actively shift the needle cannula (<b>510</b>) into a shielded state. The injection device may include a fluid dispensing interruption mechanism that automatically interrupts fluid flow when the piston driver has moved a predetermined stroke length. The injection device may also include a single pre-stressed spring acting exclusively in a linear compression mode or exclusively in a torsion mode and adapted to sequentially drive the device to enable fully automatic operation. The invention also relates to a method of sterilizing a needle cannula assembly.</p>
>> read more

ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) (Fri, 23 Aug 2013)
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
>> read more

ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1 (Fri, 23 Aug 2013)
Disclosed herein is a method for identifying TREM-1 's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1 's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1 's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
>> read more

ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) (Fri, 16 Aug 2013)
<p id="p-0001" num="0000">The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.</p>
>> read more

Medical Injection Device (Fri, 16 Aug 2013)
<p id="p-0001" num="0000">The present invention relates to medicament injection devices (<b>100</b>). A cartridge (<b>600</b>) with a septum and a needle unit (<b>500</b>) having front and rear needles (<b>510, 520</b>) are configured for relative movement from a state where the septum is sealed to a state where the septum is pierced by the rear needle (<b>520</b>). The injection device (<b>100</b>) may include a needle shield (<b>350</b>) and be configured for piercing the septum by the rear needle (<b>520</b>) when the front needle (<b>510</b>) is operated relative to the needle shield (<b>350</b>). The injection device (<b>100</b>) may also include a damping mechanism configured for limiting the speed of movement of the cartridge relative to the needle unit. The injection device (<b>100</b>) may also include an indicator generating a signal when a piston driver has travelled the complete stroke length, wherein the indicator has a deflection element that is deflected prior to or during movement of the cartridge relative to the housing.</p>
>> read more

METHODS RELATED TO TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS (Fri, 16 Aug 2013)
The present invention relates to gene markers associated with a method for predicting the clinical response in a patient suffering from an inflammatory diseases or disorders to an anti-inflammatory treatment.
>> read more

Conjugated factor VIII molecules (Thu, 15 Aug 2013)
The invention concerns B-domain truncated Factor VIII molecules with a modified circulatory half-life, wherein the molecules are covalently conjugated with a hydrophillic polymer via an O-linked oligosaccharide in the truncated B domain, and wherein factor VIII activation results in removal of the covalently conjugated hydrophillic polymer, as well as pharmaceutical compositions comprising said Factor VIII molecules.
>> read more

Conjungated factor VIII molecules (Thu, 15 Aug 2013)
The invention concerns B-domain truncated Factor VIII molecules with a modified circulatory half-life, wherein the molecules are covalently conjugated with a hydrophillic polymer via an O-linked oligosaccharide in the truncated B domain, and wherein factor VIII activation results in removal of the covalently conjugated hydrophillic polymer, as well as pharmaceutical compostiions comprising said Factor VIII molecules.
>> read more

DRUG DELIVERY DEVICE WITH CARTRIDGE FIXATION FEATURE (Fri, 02 Aug 2013)
Drug delivery system comprising a cartridge with an axially displaceable piston, and a front- loaded cartridge holder adapted to axially receive and hold a cartridge in a loaded position. The cartridge comprises first coupling means arranged at the distal portion, and the cartridge holder comprises second coupling means arranged at the distal portion, wherein the first and second coupling means are configured to engage each other to thereby axially secure a cartridge mounted in the cartridge holder.
>> read more

INJECTION DEVICE WITH A SLIDING SCALE (Fri, 02 Aug 2013)
The present invention relates to an injection device for automatic spring driven injection of a liquid drug. The injection device has a dose setting mechanism by which doses of an individual size can be set by a user, and a mechanical dose size display for displaying the size of the set dose. A housing (2) defines an interior space and has a longitudinal window (3) through which a rotatable scale drum (20) can be viewed. The scale drum (20) is coupled to a rotatable dose dial button (10) which is axially retained in relation to the housing (2) and by which the individual doses can be set. The injection device further comprises a sliding element (30) provided with a sliding window (35) and which sliding element (30) is adapted to slide axially in relation to the housing (2) during dose setting, and through which sliding window (35) indicia (22) carried by the scale drum (20) is visible such that the longitudinal window (3) and the sliding window (35) in combination with the indicia (22) form the dose size display. The rotatable scale drum (20) rotates within the interior space defined by the housing (2) during dose setting and the sliding element (30) is coupled to the scale drum (20) such that the sliding element (30) move axially within the boundaries of the housing (2) when the scale drum (20) is rotated.
>> read more

METHOD OF FORMING A COVALENT CONJUGATE BETWEEN A POLYMER AND A PEPTIDE VIA AN INTACT GLYCOSYL LINKING GROUP (Thu, 01 Aug 2013)

>> read more

Conjugated Factor VIII Molecules (Fri, 26 Jul 2013)
<p id="p-0001" num="0000">The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.</p>
>> read more

N-TERMINAL MODIFIED FGF21 COMPOUNDS (Fri, 26 Jul 2013)
<p id="p-0001" num="0000">Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).</p>
>> read more

STABILIZED FACTOR VIII VARIANTS (Fri, 19 Jul 2013)
<p id="p-0001" num="0000">The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.</p>
>> read more

Novel NIDDM Regimen (Fri, 19 Jul 2013)
<p id="p-0001" num="0000">The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.</p>
>> read more

Human Insulin Containing Additional Disulfide Bonds (Fri, 12 Jul 2013)
<p id="p-0001" num="0000">The present invention is related to human insulin containing additional disulfide bonds and methods of making such.</p>
>> read more

PREPARATION COMPRISING INSULIN, NICOTINAMIDE AND AN AMINO ACID (Thu, 11 Jul 2013)
Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.
>> read more

Insulin Analogues Containing Additional Disulfide Bonds (Fri, 05 Jul 2013)
<p id="p-0001" num="0000">The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such.</p>
>> read more

Medical skin mountable device and system (Fri, 05 Jul 2013)
<p id="p-0001" num="0000">A medical device is provided comprising a transcutaneous device unit and a process unit. The transcutaneous device unit may comprise a transcutaneous device for transporting a fluid through a skin portion of a subject, and a mounting surface adapted for application to the skin of the subject. The process unit may comprise a reservoir adapted to contain a fluid drug, the reservoir comprising an outlet means allowing the transcutaneous device to be arranged in fluid communication with an interior of the reservoir, and an expelling assembly for expelling a fluid drug out of the reservoir and through the skin of the subject via the transcutaneous device. The transcutaneous device unit and the process unit further comprise coupling means allowing the reservoir unit to be secured to the transcutaneous device unit in the situation of use. By this arrangement a two-unit system is provided which can be used in a convenient and cost-effective manner.</p>
>> read more

TORSION- SPRING BASED WIND-UP AUTOINJECTOR PEN WITH DIAL - UP/DIAL - DOWN DOSING MECHANISM (Fri, 05 Jul 2013)
The present invention relates to an automatic torsion spring based ijection device having a dial-up/dial-down mechanism by which a dose can be set by rotating a dose setting member in a first direction and which dose size can be reduced by rotating the same dose setting member in a second and opposite direction. The dial-up/dial-down mechanism operates a torsion spring which is strained when setting a dose and unstrained when rotating the dose setting element in the second direction. In order to secure the torsion spring when strained, a ratchet arm (21) following the rotation of the dose setting element in the first direction, engages a toothed element (10) such that engagement of the at least one ratchet arm (21 ) with teeth (12) of the toothed element (10) prevents unwinding of the torsion spring, and wherein the rotation of the dose setting member in the first direction moves the ratchet arm (21) from one tooth (12) to the subsequent tooth (12) of the toothed element (10), and rotation of the dose setting member in the second direction lowering the set dose activates the ratchet arm (21) to disengage the teeth (12) of the toothed element (10) and thereby allow the torsion spring to move the ratchet arm (21) in the second direction to the previous tooth (12) such that the force accumulated in the torsion spring reduces incrementally. In order to provide a smooth movement when dialling down the set dose, the at least one ratchet arm (21) is provided o a ratchet tube (20) which carries friction teeth (30) which engage with a cam curve (16) of the toothed element, dampening the movement of the ratchet arm (21) by the torsion spring.
>> read more

DIPEPTIDE COMPRISING A NON-PROTEOGENIC AMINO ACID (Fri, 05 Jul 2013)
Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
>> read more

Counteracting Drug-Induced Obesity Using GLP-1 Agonists (Fri, 28 Jun 2013)
<p id="p-0001" num="0000">The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.</p>
>> read more

N -TERMINALLY MODIFIED INSULIN DERIVATIVES (Fri, 28 Jun 2013)
The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such.
>> read more

MODIFIED ENTEROKINASE LIGHT CHAIN (Fri, 28 Jun 2013)
The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site.
>> read more

ANTI-CRAC CHANNEL ANTIBODIES (Fri, 28 Jun 2013)
The invention relates to antibodies that specifically bind to calcium release- activated calcium (CRAC) channels and inhibit the influx of calcium through CRAC channels. Such antibodies can modulate T cell activation and function.
>> read more

Insulin Derivatives Containing Additional Disulfide Bonds (Fri, 21 Jun 2013)
<p id="p-0001" num="0000">The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.</p>
>> read more

INJECTION PEN WITH MECHANICAL DOSE DISPLAY COMPRISING LARGE CIPHERS (Fri, 21 Jun 2013)
The present invention relates to an injection device (1) having a mechanical dose size dis- play wherein a first scale drum (10) carrying a series of first ciphers (11) and a second scale drum (20) carrying a series of second ciphers (21) are both rotatable and axially moveable relatively to a housing (2) of the injection device in such a way that one of the first ciphers (11) and one of the a second ciphers (21) appears simultaneously in a window provided in the housing (2) thereby informing the user of the set dose. Bothe the first scale drum (10) and the second drum (20) preferable carries five ciphers (11, 21) around one full circumferential perimeter. The ciphers (11, 21) are provided in different circumferential circles and/or helically provided.
>> read more

NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF (Fri, 14 Jun 2013)
<p id="p-0001" num="0000">Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.</p>
>> read more

Injection Device (Fri, 14 Jun 2013)
<p id="p-0001" num="0000">The invention concerns an injection device for apportioning set doses of a drug from a reservoir to a subject. The injection device comprises a housing having an interior thread formed as an outwardly pointing thread carried on an upstanding tower centrally located in the pen shaped device. This outwardly pointing thread forms a first thread connection with the interior thread of the rotatable scale drum. The injection device further comprises a driver for moving the piston rod forward when moved axially. The driver operates the piston rod through a second thread connection having a pitch different than the first thread connection.</p>
>> read more

GLP-1 AGONISTS (Fri, 14 Jun 2013)
A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist.
>> read more

COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA (Fri, 14 Jun 2013)
The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
>> read more

Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor (Fri, 07 Jun 2013)
<p id="p-0001" num="0000">The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.</p>
>> read more

KIR-Binding Agents and Methods of Use Thereof (Fri, 07 Jun 2013)
<p id="p-0001" num="0000">The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.</p>
>> read more

NOVEL GLUCAGON ANALOGUES (Fri, 07 Jun 2013)
<p id="p-0001" num="0000">The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.</p>
>> read more

GROWTH HORMONE CONJUGATES (Fri, 07 Jun 2013)
<p id="p-0001" num="0000">The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.</p>
>> read more

Process for the Preparation of Insulin-Zinc Complexes (Fri, 07 Jun 2013)
<p id="p-0001" num="0000">The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.</p>
>> read more

DRUG FILLED DELIVERY ASSEMBLY (Fri, 07 Jun 2013)
A drug delivery assembly comprises a housing (110), a piston (120) axially displaceable in the housing, and a variable volume reservoir (105) formed by the housing and the piston and containing a fluid first drug. The assembly further comprises an exterior fluid inlet (150) arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet (145) arranged in or configured to be arranged in fluid communication with the reservoir, biasing means (130) cconfigured for moving the piston forwards, and releasable retaining means (113) configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.
>> read more

Stable Multi-Dose Compositions Comprising an Antibody and a Preservative (Fri, 31 May 2013)
<p id="p-0001" num="0000">The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.</p>
>> read more

GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA (Fri, 31 May 2013)
<p id="p-0001" num="0000">The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.</p>
>> read more

Conjugated factor VIII molecules (Fri, 31 May 2013)
<p id="p-0001" num="0000">The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.</p>
>> read more

Pharmaceutical compositions containing insulin and an insulinotropic peptide (Thu, 30 May 2013)
Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
>> read more

A MAGNETIC TIME DELAY INDICATOR AND AN INJECTION DEVICE INCORPORATING SUCH (Fri, 24 May 2013)
The present invention relates to a time delay indicator (1) for an injection device for administering a drug into the body of a subject user wherein the time delay indicator is configured for indicating after administration that a dose of the drug actually has been administered and for maintaining this indication until lapse of a pre-determined time interval. The time delay indicator is based on a magnetic liquid (6) being physically moved by a magnet (10).
>> read more

MEDICAL INJECTION SYSTEM COMPRISING A MEDICAL INJECTION DEVICE AND A DOSE LIMITER MODULE (Fri, 17 May 2013)
The present invention relates to a medical injection system comprising a medical injection device (100) of the type comprising a rotatable dose setting member (160). The system further comprises a dose limiter module (200) adapted for being releasably coupled to the injection device (100). The dose limiter module (200) comprises a dose limiter base (201) and a limiter (240) arranged relative to the dose limiter base (201) so that their relative position is adjustable to set an adjusted dose limiting position. When the dose limiter module (200) is coupled to the injection device (100), the limiter (240) cooperates with the dose setting member (160) to define a blocking means for preventing rotation of the dose setting member (160) beyond the adjusted dose limiting position. The dose limiter module (200) further comprises a user operable lock (210,212,232,223,243) configured for operation between a locked state and an unlocked state to respectively prevent and enable modification of the adjusted dose limiting position, the lock (210,212,232,223,243) being configured for maintaining the lock in the locked state at least when the dose limiter module (200) is not coupled with the injection device (100).
>> read more

PROCESS FOR SHAPING A NEEDLE CANNULA (Sat, 11 May 2013)
A regular metallic, cylindrical tubular needle cannula (1) is subjected to a metal etching liquid (5) in the inside lumen (11) thereby increasing the inside diameter and enhancing the flow properties while maintaining the outside appearance. The inside diameter is only increased over a controlled length (14) of the full length of the needle cannula (10) leaving sufficient length and wall thickness to also taper the outside diameter if so wanted.
>> read more

(Fri, 03 May 2013)

>> read more

Hyperglycosylated Human Coagulation Factor IX (Fri, 19 Apr 2013)
<p id="p-0001" num="0000">The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.</p>
>> read more

LONG-ACTING Y2 RECEPTOR AGONISTS (Fri, 19 Apr 2013)
<p id="p-0001" num="0000">The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy.</p>
>> read more

Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides (Fri, 05 Apr 2013)
<p id="p-0001" num="0000">The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z<sup>1</sup>—R<sup>1</sup>)—NH—Z<sup>2</sup>—R<sup>2 </sup>motif, e.g. benzamidine compounds and guanidine compounds such as arginine.</p>
>> read more

Glucagon analogues (Fri, 29 Mar 2013)
<p id="p-0001" num="0000">The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.</p>
>> read more

NOVEL GLUCAGON ANALOGUES (Fri, 29 Mar 2013)
The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
>> read more

NOVEL GLUCAGON ANALOGUES (Fri, 29 Mar 2013)
The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.</p>
>> read more

SELECTIVE MODIFICATION OF PROTEINS (Fri, 22 Mar 2013)
<p id="p-0001" num="0000">A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.</p>
>> read more

GLP-1 DERIVATIVES (Fri, 22 Mar 2013)
The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC-(CH 2 ) x -CO-*, and Chem. 16: HOOC-C 6 H 4 -O-(CH 2 ) y -CO-*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *-NH-CH(CH 2 OH)-CO-*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.
>> read more

A PISTON ROD FOOT (Fri, 15 Mar 2013)
The invention relates to a medical drug delivery apparatus which comprises a cartridge (1) being closed at one end by a membrane (12) and at the opposite end by a movable piston (15). A piston rod foot (1) is provided for transferring the pressure from the piston rod (20) of the drug delivery apparatus and onto the piston (15). The piston rod foot (1) comprises a centre part (2) abutting the piston rod (20) and an outer part (3) which centre part (2) and outer part (3) are releasable coupled together such that the two (2, 3) can be released when a force above a certain threshold limit is applied to the outer part (3).
>> read more

PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES (Fri, 08 Mar 2013)
<p id="p-0001" num="0000">The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.</p>
>> read more

Long-Acting Gastrin Derivatives (Fri, 08 Mar 2013)
<p id="p-0001" num="0000">The present invention relates to gastrin derivatives comprising gastrin or an analogue or fragment thereof and a derivatisation group and therapeutic use thereof.</p>
>> read more

Amylin analogues and pharmaceutical compositions thereof (Fri, 08 Mar 2013)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] (Fri, 08 Mar 2013)
<p id="p-0001" num="0000">The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.</p>
>> read more

SELECTIVE MODIFICATION OF PROTEINS (Thu, 28 Feb 2013)
A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
>> read more

NOVEL GLUCAGON ANALOGUES (Thu, 07 Feb 2013)
The present invention relates to glucagon peptide agonists which have improved solubility and stability, to the use of the peptides in therapy, to methods of treatment comprising administration of the peptides to patients in need thereof, and to the use of the peptides in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hypoglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hypoglycemia, diabetes and obesity.
>> read more

NOVEL GLUCAGON ANALOGUES (Thu, 07 Feb 2013)
The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
>> read more

NOVEL GLUCAGON ANALOGUES (Thu, 07 Feb 2013)
The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
>> read more

NOVEL NIDDM REGIMEN (Fri, 01 Feb 2013)
<p id="p-0001" num="0000">The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.</p>
>> read more

ANTAGONIST ANTIBODIES AGAINST OSCAR (Fri, 25 Jan 2013)
The present disclosure relates to antagonistic antibodies against OSCAR. The present disclosure furthermore relates to use of such antibodies.
>> read more

ANTAGONISTIC ANTIBODIES AGAINST OSCAR (Fri, 25 Jan 2013)
The present disclosure relates to antagonistic antibodies against OSCAR. The present disclosure furthermore relates to use of such antibodies.
>> read more

ANTAGONISTIC ANTIBODIES AGAINST OSCAR (Fri, 25 Jan 2013)
The present disclosure relates to therapeutic antagonistic OSCAR antibodies. The present disclosure furthermore relates to use of such antibodies.
>> read more

ANTAGONISTIC ANTIBODIES AGAINST OSCAR (Fri, 25 Jan 2013)
The present disclosure relates to antagonistic antibodies against OS-CAR. The present disclosure furthermore relates to use of such antibodies.
>> read more

Polypeptides (Fri, 11 Jan 2013)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

PREPARATIVE RP-HPLC METHOD FOR PURIFYING PEPTIDES (Thu, 10 Jan 2013)
A method for separating on a RP-HPLC system a polypeptide of interest from at least one unwanted component is described, wherein at least one of the elution steps is performed at or in close proximity to the pl value of the peptide of interest.
>> read more

Anti-C5a receptor antibodies (Fri, 04 Jan 2013)
<p id="p-0001" num="0000">The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.</p>
>> read more

Polypeptides (Fri, 04 Jan 2013)
<p id="p-0001" num="0000">The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.</p>
>> read more

PEPTIDES FOR TREATMENT OF OBESITY (Thu, 03 Jan 2013)
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
>> read more

EFFICIENT INDUCTION OF DEFINITIVE ENDODERM FROM PLURIPOTENT STEM CELLS (Fri, 28 Dec 2012)
The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.
>> read more

SELECTIVE ELIMINATION OF EROSIVE CELLS (Fri, 21 Dec 2012)
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
>> read more

MULTI SUBSTITUTED INSULINS (Fri, 21 Dec 2012)
The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical cpmrising such an insulin derivative.
>> read more

THERAPEUTIC ANTIBODIES (Fri, 14 Dec 2012)
The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro- inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
>> read more

POLYPEPTIDES (Fri, 14 Dec 2012)
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
>> read more

POLYPEPTIDES (Fri, 14 Dec 2012)
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
>> read more

POLYPEPTIDES (Fri, 14 Dec 2012)
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
>> read more

Single-chain insulin (Thu, 13 Dec 2012)
The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 5-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.
>> read more

CRYSTAL OF CYTOKINE RECEPTOR (Fri, 07 Dec 2012)
Provided is a co-crystal of IL-21R and IL-21 based on its structural model. Also provided is a method of preparing a crystal of a class I cytokine receptor.
>> read more

IL-21 EPITOPE AND IL-21 LIGANDS (Fri, 07 Dec 2012)
The present invention relates to IL-21 ligands, such as e.g. antibodies, as well as use thereof.
>> read more

MEDICAL DEVICE HAVING USER FRIENDLY CONTROL INPUT (Fri, 07 Dec 2012)
The present invention relates to a medical delivery comprising a) a housing (101) adapted to accommodate a drug in a drug reservoir (110), the housing (101) having an exterior surface defining at least one non-circular section, b) a drive mechanism for expelling doses of drug from the drug reservoir (110) and c) an operable control member (150) arranged at the non-circular section of the housing, the operable control member (150) being movable relative to the non-circular section of the housing for altering a parameter relating to the operation of the medical delivery device. The operable control member (150) comprises a belt-like structure arranged to move along the non-circular section of the housing so that respective portions of the operable control member change radius of curvature as the respective portions move relative to the non-circular section of the housing.
>> read more

GLP-1 and FGF21 combinations for treatment of diabetes type 2 (Thu, 29 Nov 2012)
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of [beta] cells ex vivo in the presence of free fatty acids, on caspase activity of [beta] cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo.
>> read more

Acylated GLP-1 compounds (Fri, 23 Nov 2012)
<p id="p-0001" num="0000">Protracted GLP-1 compounds and therapeutic uses thereof.</p>
>> read more

Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices (Thu, 22 Nov 2012)
The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formu-lations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on pro-duction equipment during production of a peptide formulation.
>> read more

PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES (Thu, 22 Nov 2012)
The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.
>> read more

Stable formulations of insulinoptropic peptides (Thu, 15 Nov 2012)
The invention provides a stable formulations of insulinoptropic peptides, comprising a stable drug composite for insulinoptropic peptides.
>> read more

Preparative RP-HPLC method for purifying peptides (Thu, 08 Nov 2012)
A method for separating on a RP-HPLC system a polypeptide of interest from at least one unwanted component is described, wherein at least one of the elution steps is performed at or in close proximity to the pl value of the peptide of interest.
>> read more

Pharmaceutical compositions for oral administration of insulin peptides (Thu, 25 Oct 2012)
The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Thu, 25 Oct 2012)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K<sp>37</sp>, and the second K residue is designated K<sp>26</sp>, which derivative comprises two albumin binding moieties attached to K<sp>26</sp> and K<sp>37</sp>, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1 : HOOC-(CH<sb>2</sb>)<sb>X</sb>-CO-* Chem. 2: HOOC-C<sb>6</sb>H<sb>4</sb>-O-(CH<sb>2</sb>)<sb>y</sb>-CO-* Chem. 3: R<sp>1</sp>-C<sb>6</sb>H<sb>4</sb>-(CH<sb>2</sb>)<sb>Z</sb>-CO-* Chem. 4: HOOC-C<sb>4</sb>SH<sb>2</sb>-(CH<sb>2</sb>)<sb>W</sb>-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, R<sp>1</sp> is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH<sb>2</sb>)<sb>2</sb>-(O-(CH<sb>2</sb>)<sb>2</sb>)<sb>k</sb>-O-(CH<sb>2</sb>)<sb>n</sb>-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
>> read more

Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier (Thu, 25 Oct 2012)
The present invention relates to a solid or semisolid composition comprising a polypeptide (a), at least one polar organic solvent (b) for the polypeptide, at least one surfactant (c), at least one lipophilic component (d), and optionally at least one solid hydrophilic component (e), wherein said pharmaceutical composition is spontaneously dispersible, is provided.
>> read more

GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS (Thu, 25 Oct 2012)
The invention relates to GLP-1 receptor agonist compounds with a modified N- terminus. The compounds are of the formula Chem. 1: Y-Z-P, wherein P represents a fragment of a GLP-1 receptor agonist peptide lacking the two N-terminal amino acid residues; and Y-Z represents novel His-Ala mimetics. Examples of GLP-1 receptor agonist compounds are derived from human GLP-1 (7-37), exendin-4(1-39), or GLP-1 A (1-37). The invention also relates to derivatives of these compounds, in particular compounds with one or more albumin binding side chains capable of protracting the duration of action in vivo of these compounds. The peptides and derivatives of the invention have a good potency, a protracted pharmacokinetic profile, are stable against degradation by gastro intestinal enzymes, and/or have a high oral bioavailability. These properties are of importance in the development of GLP-1 receptor agonist compounds for subcutaneous, intravenous, and/or in particular oral administration. The invention also relates to intermediate products for use in the preparation of the GLP-1 receptor agonist compounds of the invention.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Fri, 19 Oct 2012)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1 ); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K27, and the second K residue is designated KT; which derivative comprises two albumin binding moieties attached to K27 and KT, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC-(CH2)x-CO- and HOOC-C6H4-0-(CH2)y-CO-; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula -NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.
>> read more

FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY (Fri, 19 Oct 2012)
The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.
>> read more

NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES (Thu, 11 Oct 2012)
The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide.
>> read more

MEDICAL INJECTION DEVICE WITH LARGE, MECHANICAL CIPHER DOSE DISPLAY (Fri, 05 Oct 2012)
An injection device is disclosed which comprises a housing (10) with a display for showing the size of a set dose. The display is formed from a number of individual ciphers (11, 40) which each comprises a plurality of segments (13, 14) extending horizontally and vertically. At the end of the injection device a dose setting element (20) is provided for allowing the user to set the size of the dose to be injected. Further, the display mechanism comprises a first pattern (35) for showing the vertical segments (14), and a second pattern (25) for showing the horizontal segments (13). The patterns (25, 35) are associated with the dose setting button (20) and arranged to be moved when the dose setting button (20) is operated. The injection device disclosed can have any number of ciphers (11, 40) which is coupled to each other in order to show to the user the size of any dose set.
>> read more

NOVEL GLUCAGON ANALOGUES (Fri, 05 Oct 2012)
The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
>> read more

NOVEL GLUCAGON ANALOGUES (Fri, 05 Oct 2012)
The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.</p>
>> read more

Method of purifying pegylated proteins (Fri, 28 Sep 2012)
<p id="p-0001" num="0000">The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.</p>
>> read more

HUMAN INSULIN ANALOGUES AND DERIVATIVES COMPRISING CYSTEINE SUBSTITUTIONS (Fri, 21 Sep 2012)
The present invention relates to human insulin analogues containing a substituting cysteine, to human insulin derivatives containing a PEGylated substituting cysteine and methods of making such. The compounds of the invention may be useful for the treatment of diabetes.
>> read more

Double-acylated GLP-1 derivatives (Thu, 20 Sep 2012)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1 : HOOC-(CH2)X-CO-* Chem. 2: HOOC-C6H4-O-(CH2)y-CO-* Chem. 3: R1-C6H4-(CH2)Z-CO-* Chem. 4: HOOC-C4SH2-(CH2)W-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
>> read more

Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases (Thu, 13 Sep 2012)
The present patent application concerns an enzyme capable of catalysing the conversion of a a-hydroxyglycine to an a-amide and the use of such enzymes for producing a C-terminal a-amidated peptide.
>> read more

Method for making mature insulin polypeptides (Thu, 13 Sep 2012)
The invention is related to a method for making human insulin analogues by culturing an fungi cell comprising a DNA vector encoding a precursor for human insulin analogue , wherein the said precursor comprises a connecting peptide flanked with cleavage sites at both junctions with the A- and the B-chain of the insulin peptide, respectively said cleavage sites being cleaved within the fungi cell allowing the cell to secrete high amount of correctly processed, mature two chain human insulin analogue to the culture media.
>> read more

Stable non-aqueous pharmaceutical compositions (Thu, 13 Sep 2012)
The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia. The composition comprises a dehydrated therapeutically active insulinotropic peptide, and at least one semi-polar protic organic solvent which insulinotropic peptide has been dehydrated at target pH which is at least 1pH unit from the pI of the peptide in aqueous solution.
>> read more

COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS (Sat, 08 Sep 2012)
The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.
>> read more

ANTAGONISTIC DR3 LIGANDS (Sat, 08 Sep 2012)
The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
>> read more

GLP-1 receptor agonist compounds with a modified N-terminus (Thu, 06 Sep 2012)
The invention relates to GLP-1 receptor agonist compounds with a modified N-terminus. The compounds are of the formula Chem. 1: Y-Z-P, wherein P represents a fragment of a GLP-1 receptor agonist peptide lacking the two N-terminal amino acid residues; and Y-Z represents novel His-Ala mimetics. Examples of GLP-1 receptor agonist compounds are derived from human GLP-1 (7-37), exendin-4 (1-39), or GLP-1 A (1-37). The invention also relates to derivatives of these compounds, in particular compounds with one or more albumin binding side chains capable of protracting the duration of action in vivo of these compounds. The peptides and derivatives of the invention have a good potency, a protracted pharmacokinetic profile, are stable against degradation by gastro intestinal enzymes, and/or have a high oral bioavailability. These properties are of importance in the development of GLP-1 receptor agonist compounds for subcutaneous, intravenous, and/or in particular oral administration. The invention also relates to intermediate products for use in the preparation of the GLP-1 receptor agonist compounds of the invention.
>> read more

Stable formulations of GLP-1 (Thu, 06 Sep 2012)
Stable pharmaceutical composition comprising insulinotropic peptide.
>> read more

LONG-ACTING IL-1 RECEPTOR ANTAGONISTS (Fri, 24 Aug 2012)
The present invention relates to IL-1 receptor antagonist compounds, compositions and use thereof as well as methods for preparation thereof.
>> read more

Nucleic acids encoding human anti-kir antibodies (Fri, 17 Aug 2012)
<p id="p-0001" num="0000">Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.</p>
>> read more

PURIFICATION OF INSULIN (Fri, 10 Aug 2012)
The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self- association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/Lcv ); and b)eluting the insulin peptide from said solid phase material by means of an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75 % by weight of the insulin peptide applied to the column in step (a).
>> read more

LEPTIN DERIVATIVES (Fri, 03 Aug 2012)
The invention relates to Leptin derivatives, compositions and therapeutic use there-of.
>> read more

Drug delivery device with cap functions for needle assembly (Fri, 27 Jul 2012)
<p id="p-0001" num="0000">Drug delivery system comprising a main portion with a cap as well as a needle assembly with a needle mounted in a hub and a needle cap releasably mountable on the hub to cover the needle. The cap comprises gripping means reversibly operatable between a first condition in which there is no gripping engagement between the mounted cap portion and the needle cap, this allowing the cap portion to be removed from the main portion without removing the needle cap from the hub, and a second condition in which the cap portion grippingly can engage the needle cap of a needle assembly, this allowing the needle cap to be removed from the hub together with the cap. The cap further comprises user actuation means for operating the gripping means between the two conditions.</p>
>> read more

GLP-1 PARTICLES AND COMPOSITIONS (Fri, 27 Jul 2012)
The present invention relates to compositions and particles comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised that the particle comprises a core and a surrounding layer, the core comprising the GLP-1 compound and the divalent metal, and the surrounding layer comprising the polycationic compound. The invention is particularly useful for the treatment of metabolic diseases, including diabetes.
>> read more

IL-21 LIGANDS (Fri, 27 Jul 2012)
The present invention relates to IL-21 ligands binding to a discontunous epitope on the surface of the IL-21 molecule as well as use thereof.
>> read more

GLP-1 COMPOSITIONS (Fri, 27 Jul 2012)
The present invention relates to pharmaceutical compositions comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised in that the GLP-1:divalent metal molar ratio is 1:>2. The compositions of the invention are particularly useful in the treatment of diabetes.
>> read more

MEDICAL INJECTION DEVICE (Fri, 06 Jul 2012)
The present invention relates to injection devices for injecting a dose of a medicament. The injection device (100) incorporates a housing (101), a needle assembly (150) and a cover (200). The needle assembly (150) comprises an injection needle (152, 153) accommodated in a needle container (151) having an opening which in a storage state of the injection device (100) is sealed by a film seal (155). The cover may include sections (201, 202) arranged movable relative to the housing (101). The injection device (100) is so configured that upon movement of the cover sections (201, 202) relative to the housing (101) the film seal (155) is changed from a sealing state to an unsealing state for shifting the injection device (100) into a ready-to-administer state.
>> read more

Urea glucokinase activators (Fri, 29 Jun 2012)
<p id="p-0001" num="0000">This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.</p>
>> read more

AQUEOUS FACTOR VIII SOLUTION (Fri, 22 Jun 2012)
The present invention relates to methods for stabilizing FVIII in aqueous solutions comprising a relatively high concentration of FVIII. The invention furthermore relates to such aqueous solutions as well as use thereof.
>> read more

SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID (Fri, 22 Jun 2012)
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
>> read more

PREPARATION COMPRISING INSULIN, NICOTINAMIDE AND AN AMINO ACID (Fri, 22 Jun 2012)
Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.
>> read more

A NEEDLE CANNULA WITH A COLLAPSE ZONE (Fri, 22 Jun 2012)
A metallic cylindrical tubular needle cannula (1) is subjected to a metal etching liquid inside the lumen (7) thereby increasing the inside diameter and enhancing the flow properties while maintaining the outside appearance. The inside wall (5) is further provided with a collapse zone (10) manufactured by radiating heat (11) to a specific outside area of the needle cannula (1 ) thereby increasing the aggression of the etchant. Further two different methods of in- process testing of the inside diameter of the needle cannulae using any fluid gas are disclosed.
>> read more

FAST-ACTING INSULIN IN COMBINATION WITH LONG-ACTING INSULIN (Fri, 22 Jun 2012)
Insulin preparations comprising a long-acting insulin compound, a fast-acting insulin compound, a nicotinic compound and an amino acid.
>> read more

Preparation comprising insulin, nicotinamide and an amino acid (Fri, 01 Jun 2012)
<p id="p-0001" num="0000">Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.</p>
>> read more

Ion exchange chromatography of proteins and peptides (Thu, 31 May 2012)
The present invention relates to an ion exchange chromatography process for purifying a peptide from a mixture containing said peptide and related impurities, and to an industrial method including such ion exchange chromatography process.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER (Sat, 19 May 2012)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1 : HOOC-(CH2)x-CO-*, and Chem. 2: HOOC-C6H4-0-(CH2)y-CO-*, in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises Chem. 3: *-NH-(CH2)q-CH[(CH2)w-NH2]-CO-*, wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.
>> read more

DOUBLE-ACYLATED GLP-1 DERIVATIVES (Sat, 19 May 2012)
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1 ), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem. : HOOC-(CH2)x-CO-* Chem. 2: HOOC-C6H4-0-(CH2)y-CO-* Chem. 3: R2-C6H4-(CH2)z-CO-*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *-NH-(CH2)2-(0-(CH2)2)k-0-(CH2)n-CO-*. wherein k is an integer in the range of 1 -5, and n is an integer in the range of 1 -5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
>> read more

TREATING DIABETES MELITUS USING INSULIN INJECTIONS ADMINISTERED WITH VARYING INJECTION INTERVALS (Fri, 04 May 2012)
The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof,which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.
>> read more

Hyperglycosylated human coagulation factor IX (Thu, 26 Apr 2012)
The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
>> read more

NOVEL N-TERMINALLY MODIFIED INSULIN DERIVATIVES (Fri, 20 Apr 2012)
The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such.
>> read more

GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 (Thu, 19 Apr 2012)
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice <i>in vivo</i>.
>> read more

Drug delivery device with cap functions for needle assembly (Thu, 19 Apr 2012)
Drug delivery system comprising a main portion with a cap as well as a needle assembly with a needle mounted in a hub and a needle cap releasably mountable on the hub to cover the needle. The cap comprises gripping means reversibly operatable between a first condition in which there is no gripping engagement between the mounted cap portion and the needle cap, this allowing the cap portion to be removed from the main portion without removing the needle cap from the hub, and a second condition in which the cap portion grippingly can engage the needle cap of a needle assembly, this allowing the needle cap to be removed from the hub together with the cap. The cap further comprises user actuation means for operating the gripping means between the two conditions.
>> read more

IL-21 variant nucleic acids (Fri, 06 Apr 2012)
<p id="p-0001" num="0000">IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.</p>
>> read more

Basic protein purification tags from thermophilic bacteria (Fri, 06 Apr 2012)
<p id="p-0001" num="0000">The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.</p>
>> read more

Dry mouldable drug formulation (Fri, 06 Apr 2012)
<p id="p-0001" num="0000">Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.</p>
>> read more

THERAPEUTIC FACTOR VIII ANTIBODIES (Fri, 30 Mar 2012)
The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
>> read more

FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE (Fri, 23 Mar 2012)
The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
>> read more

STABLE PHARMACEUTICAL COMPOSITIONS OF PEPTIDE DERIVATIZED USING AN OXIME LINKER (Thu, 15 Mar 2012)
The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an oxime bond.
>> read more

Anti-NKG2A antibodies and uses thereof (Thu, 08 Mar 2012)
Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
>> read more

MEDICAL INJECTION DEVICE (Fri, 02 Mar 2012)
The present invention relates to injection devices for injecting a medicament from a cartridge (600) through a needle cannula (510). The injection device (100) includes an actuator (330, 360) for driving a piston driver (310) and includes an end of stroke limiter (341, 611). When the piston driver (310) is arrested by the end of stroke limiter (341, 611) a shielding driver (370) is automatically triggered to actively shift the needle cannula (510) into a shielded state. The injection device may include a fluid dispensing interruption mechanism that automatically interrupts fluid flow when the piston driver has moved a predetermined stroke length. The injection device may also include a single pre-stressed spring acting exclusively in a linear compression mode or exclusively in a torsion mode and adapted to sequentially drive the device to enable fully automatic operation. The invention also relates to a method of sterilizing a needle cannula assembly.
>> read more

MEDICAL AUTO-INJECTION DEVICE FOR MANUAL NEEDLE INSERTION HAVING NEEDLE SHIELD, DAMPING MECHANISM AND AUDIBLE AND TACTILE FEEDBACK (Fri, 24 Feb 2012)
The present invention relates to medicament injection devices (100). A cartridge (600) with a septum and a needle unit (500) having front and rear needles (510, 520) are configured for relative movement from a state where the septum is sealed to a state where the septum is pierced by the rear needle (520). The injection device (100) may include a needle shield (350) and be configured for piercing the septum by the rear needle (520) when the front needle (510) is operated relative to the needle shield (350). The injection device (100) may also include a damping mechanism configured for limiting the speed of movement of the cartridge relative to the needle unit. The injection device (100) may also include an indicator generating a signal when a piston driver has travelled the complete stroke length, wherein the indicator has a deflection element that is deflected prior to or during movement of the cartridge relative to the housing.
>> read more

TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS (Thu, 16 Feb 2012)
The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.
>> read more

Insulin derivatives (Fri, 10 Feb 2012)
<p id="p-0001" num="0000">The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.</p>
>> read more

Peptide purification by means of hard metal ion affinity chromatography (Thu, 02 Feb 2012)
A polymer substrate functionalized with a functionality comprising at least one cyclic, metal ion coordinating ligand group which comprises at least 3 nitrogen donor atoms in the ring of the cyclic group, at least one of the nitrogen atoms having an optionally substituted carboxy(lower alkyl) or optionally substituted phosphono(lower alkyl) group covalently attached thereto, is well suited for use in conjunction with "hard" metal ions of low toxicity (such as Ca 2+ , Mg 2+ or Fe 3+ ) in the separation/purification of appropriately "tagged" polypeptides by I mmobilized M etal ion A ffinity C hromatography (IMAC).
>> read more

REMODELING AND GLYCOCONJUGATION OF PEPTIDES (Tue, 31 Jan 2012)
REMODELING AND GLYCOCONJUGATION OF PEPTIDES ABSTRACT The invention includes methods and compositions for forming a covalent conjugate of a peptide, including the addition or deletion of one more glycosyl groups to a peptide, and/or the addition of a modifying group (e.g., polymer) to a peptide. (no figure)
>> read more

GROWTH HORMONE CONJUGATES (Fri, 27 Jan 2012)
The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.
>> read more

N-TERMINAL MODIFIED FGF21 COMPOUNDS (Fri, 27 Jan 2012)
Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
>> read more

Needle magazine (Fri, 20 Jan 2012)
<p id="p-0001" num="0000">A needle magazine for holding a plurality of injection needles (<b>50</b>) is described. The needle magazine comprises a first opening adapted to receive the device fluid access portion (<b>120</b>) of a medical delivery device. Each needle (<b>50</b>) is selectively moveable from a respective storage position not aligned with said first opening into a needle mounting position aligned with said first opening. The needle magazine further comprises needle positioning means (<b>41</b>). configured to alter the mutual position between a needle selected from said plurality of needles (<b>50</b>) relative to a neighbor needle when said selected needle moves from its storage position to the needle mounting position.</p>
>> read more

STABILIZED FACTOR VIII VARIANTS (Fri, 20 Jan 2012)
The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
>> read more

A PISTON ROD FOOT (Fri, 20 Jan 2012)
The invention relates to a medical drug delivery apparatus which comprises a cartridge (1) being closed at one end by a flexible membrane (2) and at the opposite end by a movable piston (10). The movable piston rod (19) is moved forward by a piston rod (20). In order to distribute the force from the piston rod (20) to the movable piston (10) a piston rod foot (30) is provided sandwiched between the piston rod (29) and the movable piston (10) The piston rod foot (30) provided between the piston rod (20) and the movable piston (10) has a plurality of arms (34) extending in a direction perpendicular to a longitudinal axis (X) of the cartridge (1) and which arms (34) engages the inner wall (4) of the cartridge (1) thereby obtaining geometric guidance or generating a force of friction between the piston rod foot (30) and the inner wall (4) of the cartridge (1).
>> read more

INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR (Thu, 19 Jan 2012)
The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.
>> read more

SYSTEM FOR INDICATING LIFETIME STATUS FOR MEDICAL COMPONENT (Fri, 13 Jan 2012)
A drug delivery system (105, 500) is provided comprising means for receiving a reservoir assembly (230, 521) containing an amount of drug having a recommended maximum service lifetime, a delivery assembly (220, 510) adapted for cooperation with the reservoir to deliver drug there from, display means (515) for displaying information to a user, and electronic control means (210). The control means is adapted to store information representing the recommended maximum service lifetime of the reservoir assembly, detect an initial time when an operation associated with the initial use of the reservoir assembly takes place, calculate the time left until the recommended maximum service lifetime has been reached, and control the display to indicate the time left. In this way the user is automatically kept informed as to when the reservoir assembly should be replaced.
>> read more

Protease resistant insulin analogues (Thu, 12 Jan 2012)
The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.
>> read more

Liquid, aqueous pharmaceutical compositions of factor VII polypeptides (Fri, 06 Jan 2012)
<p id="p-0001" num="0000">The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a —C(═N—Z<sup>1</sup>—R<sup>1</sup>)—NH—Z<sup>2</sup>—R<sup>2 </sup>motif, e.g. benzamidine compounds and guanidine compounds such as arginine.</p>
>> read more

Liquid composition of factor VII polypeptides (Fri, 06 Jan 2012)
<p id="p-0001" num="0000">A liquid aqueous composition comprising (i) a factor VII polypeptide; (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM is described.</p>
>> read more

IMPROVED ANTIBODY BINDING AFFINITY LIGANDS (Fri, 06 Jan 2012)
The present invention discloses particularly useful ligands covalently bound to a solid support material, such as a polymer matrix, and uses thereof in the purification and/or isolation of biomolecules, such as proteins, in particular antibodies, such as monoclonal antibodies. The ligands include compounds of the formula (3,5-di-tert-butyl-4-hydroxy-benzoyl)-Arg-Arg-.
>> read more

ANTIBODIES THAT ARE CAPABLE OF SPECIFICALLY BINDING TISSUE FACTOR PATHWAY INHIBITOR (Fri, 06 Jan 2012)
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
>> read more

Antibodies against tissue factor pathway inhibitor (Fri, 30 Dec 2011)
<p id="p-0001" num="0000">The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.</p>
>> read more

Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands (Fri, 30 Dec 2011)
<p id="p-0001" num="0000">The present invention relates to a novel process for the purification of antibodies, e.g. monoclonal antibodies. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of antibodies from even closely related proteins.</p>
>> read more

PEGylated, extended insulins (Fri, 30 Dec 2011)
<p id="p-0001" num="0000">PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.</p>
>> read more

MEDICAL CONTAINER PROTECTED AGAINST CRACKING (Fri, 30 Dec 2011)
Medical containers made of plastic can be protected against cracking by adding a layer of a poly-paraxylylene structure to said container.
>> read more

INSULIN ANALOGUES CONTAINING ADDITIONAL DISULFIDE BONDS (Fri, 30 Dec 2011)
The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such.
>> read more

HUMAN INSULIN CONTAINING ADDITIONAL DISULFIDE BONDS (Fri, 30 Dec 2011)
The present invention is related to human insulin containing additional disulfide bonds and methods of making such.
>> read more

INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS (Fri, 30 Dec 2011)
The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.
>> read more

INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS (Fri, 30 Dec 2011)
The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.</p>
>> read more

Peptide purification by means of hard metal ion affinity chromatography (Thu, 29 Dec 2011)
A polymer substrate functionalized with a functionality comprising at least one cyclic, metal ion coordinating ligand group which comprises at least 3 nitrogen donor atoms in the ring of the cyclic group, at least one of the nitrogen atoms having an optionally substituted carboxy(lower alkyl) or optionally substituted phosphono(lower alkyl) group covalently attached thereto, is well suited for use in conjunction with "hard" metal ions of low toxicity (such as Ca 2+ , Mg 2+ or Fe 3+ ) in the separation/purification of appropriately "tagged" polypeptides by Immobilized Metal ion Affinity Chromatography (I MAC).
>> read more

MODIFICATION OF FACTOR VIII (Thu, 29 Dec 2011)
A Factor VIII derivative of formula (I): wherein: B represents C<sb>2</sb> to C<sb>10</sb> alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m + n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M<sp>1</sp>) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M<sp>2</sp>); or a pharmaceutically acceptable salt thereof.
>> read more

Modification of Factor VIII (Fri, 16 Dec 2011)
<p id="p-0001" num="0000">A Factor VIII derivative of formula (I): wherein: B represents C<sub>2 </sub>to C<sub>10 </sub>alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m+n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M<sup>1</sup>) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M<sup>2</sup>); or a pharmaceutically acceptable salt thereof.</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"> <img id="EMI-C00001" he="17.53mm" wi="76.12mm" file="US20110306551A1-20111215-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

Stable growth hormone compounds resistant to proteolytic degradation (Fri, 16 Dec 2011)
<p id="p-0001" num="0000">The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.</p>
>> read more

FGF21 ANALOGUES AND DERIVATIVES (Fri, 16 Dec 2011)
Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.
>> read more

Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices (Thu, 15 Dec 2011)
The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
>> read more

ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS (Fri, 09 Dec 2011)
<p id="p-0001" num="0000">This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.</p>
>> read more

Protracted exendin-4 compounds (Fri, 09 Dec 2011)
<p id="p-0001" num="0000">Novel protracted exendin-4 compounds and therapeutic uses thereof.</p>
>> read more

Coagulation factor VII polypeptides (Thu, 08 Dec 2011)
The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
>> read more

ANTI-KIR COMBINATION TREATMENTS AND METHODS (Fri, 02 Dec 2011)
<p id="p-0001" num="0000">Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.</p>
>> read more

PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES (Fri, 02 Dec 2011)
<p id="p-0001" num="0000">The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such.</p>
>> read more

Novel Insulin Analogues (Fri, 02 Dec 2011)
<p id="p-0001" num="0000">Insulin analogues wherein the B25 amino acid residue is His or Asn with the proviso that if the B25 amino acid residue is His, then the B27 amino acid residue is Asp or Glu and the A14 amino acid residue is different from Glu, have liver preferential actions.</p>
>> read more

BENDED INJECTION NEEDLE (Fri, 02 Dec 2011)
<p id="p-0001" num="0000">A method of manufacturing a bended injection needle assembly comprising the steps of: mounting a straight one-piece metallic needle cannula (<b>20</b>) in a hub (<b>1</b>), securing the straight needle cannula (<b>20</b>) to the hub (<b>1</b>) and bending the needle cannula (<b>20</b>) such that at least a part of the needle cannula deflects away from the first axis (X).</p>
>> read more

MEDICAL ASSEMBLY WITH MONITORING DEVICE (Fri, 02 Dec 2011)
<p id="p-0001" num="0000">An assembly comprises a drug delivery device and a monitoring device adapted to detect an action taking place in the drug delivery device. The drug delivery device comprises a main portion having a drug expelling mechanism for expelling drug from a reservoir through an outlet, a housing in which at least a portion of the expelling mechanism is arranged, and coupling means for a cover. The cover is adapted to cover the outlet when mounted on the main portion. The monitoring device comprises a housing portion, means for detecting an action taking place in the drug delivery device, and coupling means adapted to engage the coupling means on the main portion. By this arrangement the monitoring device can be placed in a pre-determined position relative to the main portion when the coupling means engage each other, this allowing efficient transmission of information between the monitoring device and the main portion.</p>
>> read more

STABLE MULTI-DOSE COMPOSITIONS COMPRISING AN ANTIBODY AND A PRESERVATIVE (Fri, 02 Dec 2011)
The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.
>> read more

STABLE MULTI-DOSE COMPOSITIONS COMPRISING AN ANTIBODY AND A PRESERVATIVE (Fri, 02 Dec 2011)
The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.</p>
>> read more

G6PC2-Encoded Beta Cell Surface Tags (Fri, 25 Nov 2011)
<p id="p-0001" num="0000">The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof.</p>
>> read more

Site Search